14.Aug.2018

Report Q2 2018

Consolidated sales at HUF 224,430 million, EUR 713.9 million, declined in the first half 2018 by HUF 2,359 million (1.0%) and by EUR 19.0 million (2.6%) when compared with the same period 2017. +

31.Oct.2017

Richter announces the acquisition of a minority equity stake in Prima-Temp and a related licensing agreement

Gedeon Richter Plc. today announced that it has entered into an exclusive license and distribution agreement with Prima-Temp Inc., a US, Colorado based company, to commercialize its innovative medical device, PriyaRing globally, except for the USA and Canada. PriyaRing is an internal sensor that identifies the subtle temperature changes that occur prior to ovulation. +

19.Jul.2017

European Commission approved Reagila® (cariprazine) for the treatment of schizophrenia

Gedeon Richter Plc. announces that the European Commission has granted marketing authorization to Reagila® (cariprazine) a novel antipsychotic for the treatment of schizophrenia in adult patients. +

19.May.2017

European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia

Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a positive opinion on the company’s application for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. +

14.May.2017

Report Q4 2016

Sales in 2016 increased by 6.7% in HUF and by 6.1% in EUR terms when compared to 2015. +

19.Jan.2017

Richter signed a distribution and supply agreement with Allergan

Gedeon Richter Plc. announced that it has entered into a distribution and supply agreement with Allergan to commercialize its levonorgestrel releasing Intrauterine System (IUS) in Western Europe and in other European countries under the trademark of Levosert® +

17.Jan.2017

Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

- First oral therapy to demonstrate efficacy and safety for uterine fibroids in two U.S. pivotal studies - VENUS II study reinforces efficacy, safety seen in VENUS I study, meeting all co-primary and secondary endpoints +

14.Nov.2016

Richter received positive opinion from CHMP for marketing authorisation application for biosimilar teriparatide

Gedeon Richter Plc. (“Richter”) today announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending that marketing authorization be granted for its biosimilar teriparatide, Terrosa. +

03.Nov.2016

Richter Group Report – Q3 2016

Richter Group Report - Q3 2016 +

19.Oct.2016

Acordo entre a Gedeon Richter e DM Bio na transferência de tecnologia e licenciamento de Trastuzumab biosimilar

Gedeon Richter Plc. anunciou hoje que assinou a transferência de tecnologia e contrato de licenciamento com a DM Bio ("DM Bio") no que respeita ao desenvolvimento e comercialização de anticorpo monoclonal biosimilar, Trastuzumab. +

18.Oct.2016

Acquisition of Finox Holding

Gedeon Richter Plc ("Richter")announces the acquisition of Finox Holding ("Finox"), a privately held Swiss biotech company focused on development and commercialisation of innovative and cost effective products addressing female fertility. +

09.May.2016

Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Phase III study met all co-primary and secondary endpoints and achieved statistically significant results. Allergan Plc and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy and safety of ulipristal acetate... +

13.Apr.2016

Gedeon Richter Annual Report 2015

Market capitalisation on 31 December 2015 in Euro terms was EUR 3.3 billion, about 56 percent above the EUR 2.1 billion recorded on 31 December 2014. +

29.Mar.2016

EMA started the evaluation of Richter’s marketing authorisation application for cariprazine for the treatment of schizophrenia

Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. +

08.Dec.2015

EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim

Gedeon Richter Plc. (“Richter”) today announced that the European Medicines Agency (EMA) has accepted Richter’s regulatory submission for its proposed biosimilar to Amgen’s Neulasta (pegfilgrastim). +

30.Jul.2015

Interim Report, H1 2015

Gedeon Richter Interim Report H1 2015 +

28.May.2015

European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)

This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 April 2015 and is applicable for all Member States in the European Economic Area. +

27.Apr.2015

European CHMP Issues Positive Opinion for repeated intermittent use of Esmya® 5 mg in the long term management of Uterine Fibroids

Gedeon Richter Plc. announces that the CHMP of the EMA has adopted a positive opinion on the company’s application to extend the indication of Esmya® 5 mg tablets (ulipristal acetate) to the long term repeated intermittent treatment of moderate to severe symptoms of uterine fibroids. +

27.Jan.2015

Gedeon Richter Plc. assina contrato de licenciamento e de distribuição com Bayer HealthCare para contracetivo transdérmico semanal, de baixa dosagem

Gedeon Richter Plc. anunciou hoje que assinou um contrato de licenciamento e de distribuição com a Bayer HealthCare para comercializar na União Europeia, outros países da Europa e na América Latina, um contracetivo transdérmico semanal de baixa dosagem contendo Gestodeno + Etinilestradiol, +

22.Jan.2015

Gedeon Richter Plc. Announces Positive Phase IIIb Top-line Results of Cariprazine for the Treatment of Patients with Predominant Negative Symptoms of Schizophrenia

Gedeon Richter Plc. today announced positive top-line results from a Phase IIIb trial evaluating the efficacy, safety and tolerability of cariprazine, a new atypical antipsychotic, in adult schizophrenia patients with persistent and predominant negative symptoms. +

20.Jan.2015

Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. +

06.Jan.2015

Gedeon Richter and Actavis Announce FDA Receipt of NDA Resubmission for Cariprazine

Gedeon Richter Plc. and Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission. +

06.Jan.2015

Milestone from Gedeon Richter as Palatin initiates Ph III bremelanotide study

US biopharma company Palatin Technologies says it has started its bremelanotide pivotal registration… +

29.Dec.2014

Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide... +

04.Nov.2014

Gedeon Richter Portugal patrocina edição de livro em homenagem à vida e obra do Dr. Albino Aroso

O livro “Albino Aroso - um homem à frente do seu tempo” foi apresentado no passado dia 04 Novembro, na Sede da Secção Norte da Ordem dos Médicos, com o objectivo de lembrar o propulsor das consultas de Planeamento Familiar em Portugal. +

29.Oct.2014

VI Jornadas do Médico Interno em Novembro

A Direcção de Internato Médico do Serviço de Saúde da Região (SESARAM) promove nos próximos dias 14 e 15 de Novembro, no Colégio dos Jesuítas (Reitoria da Universidade da Madeira) as VI Jornadas do Médico Interno da RAM. +

29.Oct.2014

Arrancou estudo sobre contracepção

Começou na semana passada a recolha de dados junto das mulheres sobre "Avaliação das práticas contraceptivas das mulheres em Portugal", o maior estudo nacional na área da contracepção, que pretende analisar os hábitos contraceptivos da população feminina do país entre os 15 e os 49 anos. +

20.Oct.2014

Arranca maior estudo nacional na área sobre contracepção

Começa hoje a recolha de dados junto das mulheres sobre "Avaliação das práticas contraceptivas das mulheres em Portugal", o maior estudo nacional na área da contracepção, que pretende analisar os hábitos contraceptivos da população feminina do país entre os 15 e os 49 anos. +

03.Sep.2014

Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter

Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement, to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD)... +

31.Mar.2014

Gedeon Richter Plc. and Forest Laboratories, Inc. Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression

Gedeon Richter Plc. and Forest Laboratories, Inc. (NYSE: FRX) announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. +